Kezdőlap › Nem kis sejtes tüdőrák › Kalifornia › San Diego
Nem kis sejtes tüdőrák klinikai vizsgálatok: San Diego, CA
48 Nem kis sejtes tüdőrák vizsgálat keres résztvevőket San Diego és környéke (kb. 30 mérföldes körzetben) helyszínein. Nyissa meg a vizsgálatot, hogy lássa, ki csatlakozhat, és hogyan léphet kapcsolatba a csapattal.
Hivatalos vizsgálati szöveg (angol)
Vizsgálatra keres résztvevőket? Emelje ki az oldal tetején — $99 / 30 nap →
A Study to Assess Adverse Events and Change in Disease Activity of Intravenous (IV) Telisotuzumab Adizutecan, Monotherapy or in Combination With Osimertinib, Compared to Standard of Care in Adult Participants With Locally Advanced or Metastatic EGFR-Mutated Non-Squamous Non-Small Cell Lung Cancer
Toborzás folyamatban2/3. fázis
- UC San Diego Health - Moores Cancer Center /ID# 278836, La Jolla · 11 mérföldre
Testing the Addition of a Type of Drug Called Immunotherapy to the Usual Chemotherapy Treatment for Non-small Cell Lung Cancer, an ALCHEMIST Treatment Trial (Chemo-IO [ACCIO])
Toborzás folyamatban3. fázis
- Kaiser Permanente-San Diego Zion, San Diego
- UC San Diego Moores Cancer Center, La Jolla · 11 mérföldre
A Study of LY4052031 in Participants With Advanced or Metastatic Urothelial Cancer or Other Solid Tumors
Toborzás folyamatban1. fázis
- University of California, San Diego (UCSD) - Moores Cancer Center, La Jolla · 11 mérföldre
The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)
Toborzás folyamatban1/2. fázis
- University of San Diego Moores Cancer Center, La Jolla · 11 mérföldre
Immunotherapy After Surgery for People Who Have No Remaining Cancer Cells After Standard Treatment for Early-Stage Non-Small Cell Lung Cancer, INSIGHT Trial
Toborzás folyamatban3. fázis
- UC San Diego Moores Cancer Center, La Jolla · 11 mérföldre
Open-Label Study of BBO-10203 in Subjects With Advanced Solid Tumors
Toborzás folyamatban1. fázis
- University of California San Diego Moores Cancer Center, San Diego
A First in Human Study of ALX2004 With Advanced or Metastatic Selected Solid Tumors
Toborzás folyamatban1. fázis
- ALX Center 9, La Jolla · 11 mérföldre
A Study of PHN-012 in Patients With Advanced Solid Tumors
Toborzás folyamatban1. fázis
- PHN-012-001 Site, San Diego
A Study of Amivantamab in Participants With Advanced or Metastatic Solid Tumors Including Epidermal Growth Factor Receptor (EGFR)-Mutated Non-Small Cell Lung Cancer
Toborzás folyamatban2. fázis
- University of California at San Diego, La Jolla · 11 mérföldre
A Study to Learn About the Study Medicine Called PF-08046054/SGN-PDL1V Versus Docetaxel in Adult Participants With Previously-Treated Programmed Cell Death Ligand 1 (PD-L1) Positive Non-Small-Cell Lung Cancer (NSCLC)
Toborzás folyamatban3. fázis
- UC San Diego McGrath Outpatient Pavilion - Hillcrest, San Diego
- UC San Diego Medical Center - Hillcrest, San Diego
- UCSD Medical Center - Rancho Bernardo, San Diego
- és további 3
Solid Tumor Analysis for HLA Loss of Heterozygosity (LOH) and Apheresis for CAR T- Cell Manufacturing
Toborzás folyamatbanMegfigyeléses tanulmány
- University of California San Diego, La Jolla · 11 mérföldre
A Study of JNJ-90301900 in Combination With Chemoradiation Followed by Consolidation Immunotherapy for Non-Small Cell Lung Cancer (NSCLC)
Toborzás folyamatban2. fázis
- Moores Cancer Center at UC San Diego Health, La Jolla · 11 mérföldre
A Study of Amivantamab in Combination With Lazertinib, or Amivantamab in Combination With Platinum-Based Chemotherapy, for Common Epidermal Growth Factor Receptor (EGFR)-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)
Toborzás folyamatban2. fázis
- University of California San Diego Health, La Jolla · 11 mérföldre
Symbiotic-Lung-20: A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Different Anticancer Agents in Advanced Cancers
Toborzás folyamatban1/2. fázis
- Scripps Clinic Torrey Pines (Scripps Cancer Center), La Jolla · 11 mérföldre
- Scripps Green Hospital, La Jolla · 11 mérföldre
- Scripps Shiley Pavilion, La Jolla · 11 mérföldre
Study of Olomorasib (LY3537982) in Combination With Standard of Care in Participants With Resected or Unresectable KRAS G12C-mutant Non-Small Cell Lung Cancer
Toborzás folyamatban3. fázis
- Kaiser Permanente San Diego Mission Road, San Diego
Pan-tumor MRD Study
Toborzás folyamatbanMegfigyeléses tanulmány
- Medical Oncology Associates of San Diego (MOASD), San Diego
- Medical Oncology Associates of San Diego, San Diego
Intratumoral N17350 in Advanced Solid Tumors
Toborzás folyamatban1/2. fázis
- Scripps Clinic Torrey Pines - La Jolla, San Diego
Safety, Efficacy, and Pharmacokinetics of BNT327 in Combination With Chemotherapy and Other Investigational Agents for Lung Cancer
Toborzás folyamatban2/3. fázis
- University Of California - San Diego Moores Cancer Center, La Jolla · 11 mérföldre
Clinical Study of Ivonescimab for First-line Treatment of Metastatic NSCLC Patients With High PD-L1
Toborzás folyamatban3. fázis
- Clinical Study Site, San Diego
ORACLE: Observation of ResiduAl Cancer With Liquid Biopsy Evaluation
Toborzás folyamatbanMegfigyeléses tanulmány
- University of California, San Diego, La Jolla · 11 mérföldre
A Phase 1/1b Study of IAM1363 in HER2 Cancers
Toborzás folyamatban1. fázis
- UCSD Moores Cancer Center, La Jolla · 11 mérföldre
A Study of Sofe-M in Participants With Selected Advanced Solid Tumors
Toborzás folyamatban1. fázis
- University of California, San Diego (UCSD) - Moores Cancer Center, La Jolla · 11 mérföldre
Phase III Study of Datopotamab Deruxtecan Versus Docetaxel in Previously Treated TROP2-positive Advanced or Metastatic Non-squamous NSCLC Without Actionable Genomic Alterations
Toborzás folyamatban3. fázis
- Research Site, San Diego
- Research Site, La Jolla · 11 mérföldre
Open-label Study of BBO-8520 in Adult Subjects With KRASG12C Non-small Cell Lung Cancer
Toborzás folyamatban1. fázis
- University of California - San Diego Moores Cancer Center, La Jolla · 11 mérföldre
Pembrolizumab With or Without Maintenance Sacituzumab Tirumotecan (Sac-TMT; MK-2870) in Metastatic Squamous Non-small Cell Lung Cancer (NSCLC) [MK-2870-023]
Toborzás folyamatban3. fázis
- Sharp Memorial Hospital ( Site 9544), San Diego
FT836 With or Without Chemotherapy and/or Monoclonal Antibodies, in Participants With Advanced Solid Tumors
Toborzás folyamatban1. fázis
- UC San Diego Moores Cancer Center, La Jolla · 11 mérföldre
A Study to Evaluate KIN-2787 in Participants With BRAF and/or NRAS Mutation Positive Solid Tumors
Toborzás folyamatban1. fázis
- University of California San Diego, Moores Cancer Center, San Diego
Phase III, Open-label Study of First-line Osimertinib With or Without Datopotamab Deruxtecan for EGFRm Locally Advanced or Metastatic Non-small Cell Lung Cancer
Toborzás folyamatban3. fázis
- Research Site, San Diego
Study to Assess the Efficacy and Safety of Rina-S in Participants With Non-small Cell Lung Cancer
Toborzás folyamatban2. fázis
- Kaiser Permanente San Diego Mission Road, San Diego
Testing Proton Craniospinal Radiation Therapy Versus the Usual Radiation Therapy for Leptomeningeal Metastasis, RADIATE-LM Trial
Toborzás folyamatban3. fázis
- UC San Diego Medical Center - Hillcrest, San Diego
- California Protons Cancer Therapy Center, San Diego
- UC San Diego Moores Cancer Center, La Jolla · 11 mérföldre
A Study of BH-30643 in Subjects With Locally Advanced or Metastatic NSCLC Harboring EGFR and/or HER2 Mutations
Toborzás folyamatban1/2. fázis
- UC San Diego Moores Cancer Center, La Jolla · 11 mérföldre
Rinatabart Sesutecan (Rina-S, PRO1184, GEN1184) for Advanced Solid Tumors (GCT1184-01/ PRO1184-001)
Toborzás folyamatban1/2. fázis
- University of California, San Diego; Moores Cancer Center, San Diego
Study of RAS(ON) Inhibitors in Patients With Advanced RAS-mutated NSCLC
Toborzás folyamatban1/2. fázis
- University of California, San Diego Moores Cancer Center, San Diego
A Study to Evaluate the Safety and Efficacy of Mesothelin-Targeting Logic-gated CAR T, in Participants With Solid Tumors That Express MSLN and Have Lost HLA-A*02 Expression
Toborzás folyamatban1/2. fázis
- UCSD Moores Cancer Center, La Jolla · 11 mérföldre
Comparing Combinations of Targeted Drugs for Advanced Non-Small Cell Lung Cancer That Has EGFR and MET Gene Changes (A Lung-MAP Treatment Trial)
Toborzás folyamatban2. fázis
- UC San Diego Moores Cancer Center, La Jolla · 11 mérföldre
BBO-11818 in Adult Subjects With KRAS Mutant Cancer
Toborzás folyamatban1. fázis
- University of California San Diego Moores Cancer Center, San Diego
A Study to Investigate the Efficacy and Safety of Dato-DXd With or Without Osimertinib Compared With Platinum Based Doublet Chemotherapy in Participants With EGFR-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer
Toborzás folyamatban3. fázis
- Research Site, San Diego
- Research Site, La Jolla · 11 mérföldre
Targeted Treatment for Advanced Non-Small Cell Lung Cancer That Has Increased Copies of the MET Gene (An Expanded Lung-MAP Treatment Trial)
Toborzás folyamatban2. fázis
- UC San Diego Moores Cancer Center, La Jolla · 11 mérföldre
Adding the Immunotherapy Drug Cemiplimab to Usual Treatment for People With Advanced Non-Small Cell Lung Cancer Who Had Previous Treatment With Platinum Chemotherapy and Immunotherapy (An Expanded Lung-MAP Treatment Trial)
Toborzás folyamatban2/3. fázis
- Kaiser Permanente-San Diego Zion, San Diego
- UC San Diego Moores Cancer Center, La Jolla · 11 mérföldre
Targeted Treatment for Advanced Non-Small Cell Lung Cancer That Has a MET Exon 14 Skipping Gene Change (An Expanded Lung-MAP Treatment Trial)
Toborzás folyamatban2. fázis
- UC San Diego Moores Cancer Center, La Jolla · 11 mérföldre
A Study to Evaluate the Efficacy and Safety of Sutetinib Maleate Capsule in Locally Advanced or Metastatic NSCLC
Toborzás folyamatban2. fázis
- University of California San Diego Moores Cancer Center, La Jolla · 11 mérföldre
A Study Evaluating FMC-376 in Participants With KRAS G12C Mutated Solid Tumors
Toborzás folyamatban1/2. fázis
- University of California San Diego (UC San Diego) Health - Jacobs Medical Center - Moores Cancer Center, La Jolla · 11 mérföldre
A Phase 1/2 Clinical Trial to Assess the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of HMBD-501 in Patients With HER3-Expressing Solid Tumors
Toborzás folyamatban1/2. fázis
- Research Site, La Jolla · 11 mérföldre
EZH2 Inhibitor, Tulmimetostat, and PD-1 Blockade for Treatment of Advanced Non-small Cell Lung Cancer
Toborzás folyamatban1/2. fázis
- VA San Diego Healthcare System, San Diego, CA, San Diego
Retifanlimab and Ruxolitinib In Solid Malignancies
Toborzás folyamatban1/2. fázis
- University of California, San Diego Moores Cancer Center, La Jolla · 11 mérföldre
SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry
Toborzás folyamatbanMegfigyeléses tanulmány
- Massive Bio SYNERGY-AI site, La Jolla · 11 mérföldre
A Study to Evaluate the Safety and Efficacy of A2B395, an Allogeneic Logic-gated CAR T, in Participants With Solid Tumors That Express EGFR and Have Lost HLA-A*02 Expression
Toborzás folyamatban1/2. fázis
- UCSD Moores Cancer Center, La Jolla · 11 mérföldre
Study of CRX100 as Monotherapy and in Combination With Pembrolizumab in Patients With Advanced Solid Malignancies
Toborzás folyamatban1. fázis
- UC San Diego Moores Cancer Center, La Jolla · 11 mérföldre
Nem kis sejtes tüdőrák vizsgálatok más városokban
- Houston, TX145 tanulmány
- New York City, NY121 tanulmány
- Arlington, VA104 tanulmány
- Nashville, TN97 tanulmány
- Boston, MA90 tanulmány
- Los Angeles, CA87 tanulmány
- St. Louis, MO73 tanulmány
- Chicago, IL61 tanulmány
- Baltimore, MD60 tanulmány
- San Antonio, TX59 tanulmány
- Columbus, OH57 tanulmány
- Washington, DC55 tanulmány
Egyéb vizsgálatok: San Diego
- Mellrák41 tanulmány
- Rák (minden típus)32 tanulmány
- Prosztatarák31 tanulmány
- Áttétes rák30 tanulmány
- Kolorektális rák25 tanulmány
- Petefészekrák24 tanulmány
- Hasnyálmirigyrák24 tanulmány
- Tüdőrák23 tanulmány
- Elhízás23 tanulmány
- Szívelégtelenség23 tanulmány
- Depresszió21 tanulmány
- Melanóma18 tanulmány
Forrás: ClinicalTrials.gov, adatok lekérve: 2026. okt. 6.. Minden vizsgálat saját alkalmassági feltételeket határoz meg; a döntést a vizsgálati csapat hozza meg.